News for Wave Life Sciences Ltd. (WVE)

On June 13, 2025, Gregory Verdine, a Director at WAVE Life Sciences Ltd (WVE), sold 30,000 shares of the company. Following this transaction, the insider now ow

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. ( WVE), a clinical-stage biotechnology company focused on unlocking the broad poten

Wave Life Sciences (WVE) to participate in the 2025 Jefferies Global Healthcare Conference. Company CEO Paul Bolno to lead a discussion on June 4, 2025,

We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at where Wave Life Sciences Ltd. (NASDAQ:WVE) stands against other best low priced biotech stocks to buy now. Is Now the Time to Buy Biotech Stocks? On May 8, Michael […]

On May 8, Michael Yee, Senior Biotech Analyst at Jefferies, appeared on CNBC to discuss how tariffs and policy risks are pressuring the biotech industry, while simultaneously iterating that low valuations...

Wave Life Sciences Ltd. (NASDAQ:WVE) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsKate Rausch - Vice President, Investor...

Release Date: May 08, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points WAVE Life Science

WAVE Life Sciences Ltd's innovative PRISM platform positions it at the forefront of RNA medicine development.Despite a strong research pipeline, WAVE faces sig

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NWVE.OQ - WAVE Life Sciences LtdQ1 2025 WAVE Life Sciences Ltd Earnings CallMay 08, 2025 / 12:3

**media[618864]**

Wave Life Sciences Ltd. shares promising updates on AATD & DMD treatments. Click here for my updated look at WVE stock prospects.

Revenue (Q4 2024): $83.7 million.Revenue (Full Year 2024): $108.3 million.Research and Development Expenses (Q4 2024): $44.6 million.Research and Development E

Wave Life Sciences Ltd. (NASDAQ:WVE) Q4 2024 Earnings Conference Call March 4, 2025 8:30 AM ETCompany ParticipantsKate Rausch - VP, IR & Corporate...

WAVE Life Sciences Ltd (WVE), a clinical-stage biotechnology company, has announced its financial results for the fourth quarter and full year ending December 3

Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first single dose cohort Multi-dosing ong

**media[556711]**

WAVE Life Sciences Ltd (WVE) is set to release its Q4 2024 earnings on Mar 4, 2025. The consensus estimate for Q4 2024 revenue is $28.04 million, and the earnin

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

WAVE Life Sciences Ltd (WVE), a clinical-stage biotechnology company dedicated to advancing RNA medicines, has announced a live webcast and conference call sche